Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma

Liqiang Xi, Trinh Hoc Tran Pham, Eden C. Payabyab, Richard M. Sherry, Steven A. Rosenberg, Mark Raffeld

Research output: Contribution to journalArticle

Abstract

Purpose: Adoptive transfer of activated autologous tumorinfiltrating lymphocytes (TIL) can mediate complete, durable regressions in patients with metastatic melanoma. Responding patients generally do not have significant changes in noncutaneous RECIST targets before 30 to 60 days following TIL infusion, and complete responses are often not confirmed for 1 to 2 years. There is a critical need for a biomarker that can provide early information regarding the likelihood and duration of a response to enable rational decisions about altering therapy. We wished to evaluate the role of circulating tumor DNA (ctDNA) in separating responding from nonresponding patients. Experimental Design: We studied BRAF V600E ctDNA levels by a sensitive allele-specific PCR assay in 388 serum samples from 48 patients who received TIL immunotherapy at the NCI and correlated differences in the dynamic patterns of their ctDNA measurements with response outcomes. Results: A strong correlation was found between the presence or absence of an early serum peak of V600E ctDNA, and the likelihood of an objective response. Furthermore, patients that developed an early ctDNA peak and cleared their serum of V600E ctDNA were highly likely to achieve a complete response over the next 1 to 2 years. Patients that showed no peak of V600E ctDNA failed to achieve an objective response, with one exception. Conclusions: We show that the dynamic changes occurring in BRAF V600E ctDNA levels within the first month following T-cell transfer immunotherapy in metastatic melanoma can be used to rapidly identify responding from nonresponding patients, potentially allowing clinicians to make critical treatment-related decisions in a more timely manner. These data also suggest that the majority of tumor killing by TIL occurs very early after the initiation of therapy.

Original languageEnglish (US)
Pages (from-to)5480-5486
Number of pages7
JournalClinical Cancer Research
Volume22
Issue number22
DOIs
StatePublished - Nov 15 2016
Externally publishedYes

Fingerprint

Immunotherapy
Melanoma
T-Lymphocytes
DNA
Neoplasms
Lymphocytes
Serum
Adoptive Transfer
Research Design
Therapeutics
Biomarkers
Alleles
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma. / Xi, Liqiang; Pham, Trinh Hoc Tran; Payabyab, Eden C.; Sherry, Richard M.; Rosenberg, Steven A.; Raffeld, Mark.

In: Clinical Cancer Research, Vol. 22, No. 22, 15.11.2016, p. 5480-5486.

Research output: Contribution to journalArticle

Xi, Liqiang ; Pham, Trinh Hoc Tran ; Payabyab, Eden C. ; Sherry, Richard M. ; Rosenberg, Steven A. ; Raffeld, Mark. / Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 22. pp. 5480-5486.
@article{1e0eee2862534590b368212d330d0302,
title = "Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma",
abstract = "Purpose: Adoptive transfer of activated autologous tumorinfiltrating lymphocytes (TIL) can mediate complete, durable regressions in patients with metastatic melanoma. Responding patients generally do not have significant changes in noncutaneous RECIST targets before 30 to 60 days following TIL infusion, and complete responses are often not confirmed for 1 to 2 years. There is a critical need for a biomarker that can provide early information regarding the likelihood and duration of a response to enable rational decisions about altering therapy. We wished to evaluate the role of circulating tumor DNA (ctDNA) in separating responding from nonresponding patients. Experimental Design: We studied BRAF V600E ctDNA levels by a sensitive allele-specific PCR assay in 388 serum samples from 48 patients who received TIL immunotherapy at the NCI and correlated differences in the dynamic patterns of their ctDNA measurements with response outcomes. Results: A strong correlation was found between the presence or absence of an early serum peak of V600E ctDNA, and the likelihood of an objective response. Furthermore, patients that developed an early ctDNA peak and cleared their serum of V600E ctDNA were highly likely to achieve a complete response over the next 1 to 2 years. Patients that showed no peak of V600E ctDNA failed to achieve an objective response, with one exception. Conclusions: We show that the dynamic changes occurring in BRAF V600E ctDNA levels within the first month following T-cell transfer immunotherapy in metastatic melanoma can be used to rapidly identify responding from nonresponding patients, potentially allowing clinicians to make critical treatment-related decisions in a more timely manner. These data also suggest that the majority of tumor killing by TIL occurs very early after the initiation of therapy.",
author = "Liqiang Xi and Pham, {Trinh Hoc Tran} and Payabyab, {Eden C.} and Sherry, {Richard M.} and Rosenberg, {Steven A.} and Mark Raffeld",
year = "2016",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-16-0613",
language = "English (US)",
volume = "22",
pages = "5480--5486",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Circulating tumor DNA as an early indicator of response to T-cell transfer immunotherapy in metastatic melanoma

AU - Xi, Liqiang

AU - Pham, Trinh Hoc Tran

AU - Payabyab, Eden C.

AU - Sherry, Richard M.

AU - Rosenberg, Steven A.

AU - Raffeld, Mark

PY - 2016/11/15

Y1 - 2016/11/15

N2 - Purpose: Adoptive transfer of activated autologous tumorinfiltrating lymphocytes (TIL) can mediate complete, durable regressions in patients with metastatic melanoma. Responding patients generally do not have significant changes in noncutaneous RECIST targets before 30 to 60 days following TIL infusion, and complete responses are often not confirmed for 1 to 2 years. There is a critical need for a biomarker that can provide early information regarding the likelihood and duration of a response to enable rational decisions about altering therapy. We wished to evaluate the role of circulating tumor DNA (ctDNA) in separating responding from nonresponding patients. Experimental Design: We studied BRAF V600E ctDNA levels by a sensitive allele-specific PCR assay in 388 serum samples from 48 patients who received TIL immunotherapy at the NCI and correlated differences in the dynamic patterns of their ctDNA measurements with response outcomes. Results: A strong correlation was found between the presence or absence of an early serum peak of V600E ctDNA, and the likelihood of an objective response. Furthermore, patients that developed an early ctDNA peak and cleared their serum of V600E ctDNA were highly likely to achieve a complete response over the next 1 to 2 years. Patients that showed no peak of V600E ctDNA failed to achieve an objective response, with one exception. Conclusions: We show that the dynamic changes occurring in BRAF V600E ctDNA levels within the first month following T-cell transfer immunotherapy in metastatic melanoma can be used to rapidly identify responding from nonresponding patients, potentially allowing clinicians to make critical treatment-related decisions in a more timely manner. These data also suggest that the majority of tumor killing by TIL occurs very early after the initiation of therapy.

AB - Purpose: Adoptive transfer of activated autologous tumorinfiltrating lymphocytes (TIL) can mediate complete, durable regressions in patients with metastatic melanoma. Responding patients generally do not have significant changes in noncutaneous RECIST targets before 30 to 60 days following TIL infusion, and complete responses are often not confirmed for 1 to 2 years. There is a critical need for a biomarker that can provide early information regarding the likelihood and duration of a response to enable rational decisions about altering therapy. We wished to evaluate the role of circulating tumor DNA (ctDNA) in separating responding from nonresponding patients. Experimental Design: We studied BRAF V600E ctDNA levels by a sensitive allele-specific PCR assay in 388 serum samples from 48 patients who received TIL immunotherapy at the NCI and correlated differences in the dynamic patterns of their ctDNA measurements with response outcomes. Results: A strong correlation was found between the presence or absence of an early serum peak of V600E ctDNA, and the likelihood of an objective response. Furthermore, patients that developed an early ctDNA peak and cleared their serum of V600E ctDNA were highly likely to achieve a complete response over the next 1 to 2 years. Patients that showed no peak of V600E ctDNA failed to achieve an objective response, with one exception. Conclusions: We show that the dynamic changes occurring in BRAF V600E ctDNA levels within the first month following T-cell transfer immunotherapy in metastatic melanoma can be used to rapidly identify responding from nonresponding patients, potentially allowing clinicians to make critical treatment-related decisions in a more timely manner. These data also suggest that the majority of tumor killing by TIL occurs very early after the initiation of therapy.

UR - http://www.scopus.com/inward/record.url?scp=84995917584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995917584&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-0613

DO - 10.1158/1078-0432.CCR-16-0613

M3 - Article

VL - 22

SP - 5480

EP - 5486

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -